

# Anna Rita Bentivoglio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7019374/publications.pdf>

Version: 2024-02-01

165  
papers

14,810  
citations

29994

54  
h-index

19136

118  
g-index

166  
all docs

166  
docs citations

166  
times ranked

13170  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1. <i>Science</i> , 2004, 304, 1158-1160.	6.0	3,060
2	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	2.2	1,171
3	Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36. <i>American Journal of Human Genetics</i> , 2001, 68, 895-900.	2.6	459
4	PINK1 mutations are associated with sporadic early-onset parkinsonism. <i>Annals of Neurology</i> , 2004, 56, 336-341.	2.8	447
5	Analysis of blink rate patterns in normal subjects. <i>Movement Disorders</i> , 1997, 12, 1028-1034.	2.2	394
6	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 578-586.	2.2	382
7	A Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure. <i>New England Journal of Medicine</i> , 1999, 341, 65-69.	13.9	373
8	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. <i>Brain</i> , 2010, 133, 2664-2676.	3.7	367
9	A Comparison of Botulinum Toxin and Saline for the Treatment of Chronic Anal Fissure. <i>New England Journal of Medicine</i> , 1998, 338, 217-220.	13.9	339
10	The role of small intestinal bacterial overgrowth in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1241-1249.	2.2	267
11	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 1371-1374.	2.2	265
12	Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 398-406.	2.6	250
13	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	4.9	248
14	Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. <i>Urology</i> , 2003, 62, 259-264.	0.5	220
15	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752.	1.4	197
16	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An 18F-dopa PET study. <i>Annals of Neurology</i> , 2002, 52, 849-853.	2.8	192
17	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	1.8	188
18	Botulinum toxin for chronic anal fissure. <i>Lancet</i> , The, 1994, 344, 1127-1128.	6.3	187

#	ARTICLE	IF	CITATIONS
19	Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. <i>Surgery</i> , 2002, 131, 179-184.	1.0	163
20	Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. <i>American Journal of Surgery</i> , 2000, 179, 46-50.	0.9	147
21	Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson's Disease. <i>Movement Disorders</i> , 2011, 26, 889-892.	2.2	145
22	Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1154-1161.	2.2	140
23	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	1.8	140
24	Botulinum Toxin Injections in the Internal Anal Sphincter for the Treatment of Chronic Anal Fissure. <i>Annals of Surgery</i> , 1998, 228, 664-669.	2.1	133
25	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001, 49, 362-366.	2.8	118
26	Ageing is associated with a diffuse impairment of forebrain cholinergic neurons. <i>Brain Research</i> , 1990, 508, 51-59.	1.1	117
27	Management of status dystonicus: Our experience and review of the literature. <i>Movement Disorders</i> , 2007, 22, 963-968.	2.2	115
28	Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 313-319.	2.2	111
29	Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 559-561.	2.2	102
30	Park6-linked parkinsonism occurs in several european families. <i>Annals of Neurology</i> , 2002, 51, 14-18.	2.8	98
31	Effects of Bilateral Subthalamic Nucleus Stimulation and Medication on Parkinsonian Speech Impairment. <i>Journal of Voice</i> , 2008, 22, 365-372.	0.6	98
32	Zolpidem in Progressive Supranuclear Palsy. <i>New England Journal of Medicine</i> , 1999, 341, 543-544.	13.9	97
33	The influence of gender on phenotype and disease progression in patients with Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 192-197.	1.1	96
34	Status dystonicus: Predictors of outcome and progression patterns of underlying disease. <i>Movement Disorders</i> , 2012, 27, 783-788.	2.2	94
35	Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.	2.2	93
36	<sc><i>GBA</i></sc>-Related Parkinson's Disease: Dissection of Genotypeâ€œPhenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111.	2.2	83

#	ARTICLE	IF	CITATIONS
37	Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study. <i>Psychiatry Research</i> , 2014, 215, 448-452.	1.7	81
38	Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinson's Disease: Results from the EXosomes in Parkinson's Disease (EXPAND) Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 504.	1.0	80
39	Severe constipation in parkinson's disease relieved by botulinum toxin. <i>Movement Disorders</i> , 1997, 12, 764-766.	2.2	75
40	Cocaine addiction: From habits to stereotypical-repetitive behaviors and punning. <i>Drug and Alcohol Dependence</i> , 2008, 96, 178-182.	1.6	75
41	GPi-DBS in Huntington's disease: Results on motor function and cognition in a 72-year-old case. <i>Movement Disorders</i> , 2008, 23, 1289-1292.	2.2	74
42	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	1.1	74
43	Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson's Disease: Rationale, Design and Methods of the EXosomes in Parkinson Disease (EXPAND) Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2373.	1.8	72
44	Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 376-380.	0.7	71
45	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long-term observation. <i>Movement Disorders</i> , 2009, 24, 555-561.	2.2	71
46	Tremor in primary adult-onset dystonia: prevalence and associated clinical features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 404-408.	0.9	71
47	Treatment of Outlet Obstruction Constipation in Parkinson'S Disease With Botulinum Neurotoxin A. <i>American Journal of Gastroenterology</i> , 2003, 98, 1439-1440.	0.2	67
48	Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. <i>Neurotoxicity Research</i> , 2009, 15, 224-231.	1.3	66
49	Clinical differences between botulinum neurotoxin type A and B. <i>Toxicon</i> , 2015, 107, 77-84.	0.8	64
50	Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 695-701.	1.9	62
51	Novel mutations in <i>SPG11</i> cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism. <i>Movement Disorders</i> , 2011, 26, 553-556.	2.2	62
52	Impulsive-compulsive behaviors in <i>parkin</i> -associated Parkinson disease. <i>Neurology</i> , 2016, 87, 1436-1441.	1.5	61
53	Polysomnographic Findings and Clinical Correlates in Huntington Disease: A Cross-Sectional Cohort Study. <i>Sleep</i> , 2015, 38, 1489-1495.	0.6	57
54	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 548.e9-548.e18.	1.5	56

#	ARTICLE	IF	CITATIONS
55	Neuropsychological features of patients with Parkinson's disease and impulse control disorders. <i>Neurological Sciences</i> , 2013, 34, 1207-1213.	0.9	56
56	Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 299-303.	1.1	55
57	Frequency and phenotypic spectrum of <i>KMT2B</i> dystonia in childhood: A single-center cohort study. <i>Movement Disorders</i> , 2019, 34, 1516-1527.	2.2	55
58	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 1980-1989.	0.7	53
59	Genome-wide association study in musician's dystonia: A risk variant at the arylsulfatase G locus?. <i>Movement Disorders</i> , 2014, 29, 921-927.	2.2	53
60	Aceruloplasminemia: A novel mutation in a family with marked phenotypic variability. <i>Movement Disorders</i> , 2008, 23, 751-755.	2.2	52
61	Reduced facial expressiveness in Parkinson's disease: A pure motor disorder?. <i>Journal of the Neurological Sciences</i> , 2015, 358, 125-130.	0.3	52
62	The Long-term Effect of Tetrabenazine in the Management of Huntington Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 313-318.	0.2	50
63	Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. <i>Toxicon</i> , 2015, 107, 129-140.	0.8	50
64	Tetrabenazine. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2883-2896.	0.9	49
65	Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1937-1948.	3.3	49
66	Age-dependent loss of cholinergic neurones in basal ganglia of rats. <i>Brain Research</i> , 1988, 455, 177-181.	1.1	48
67	Phenotypic variability of PINK1 expression: 12 Years' clinical follow-up of two Italian families. <i>Movement Disorders</i> , 2014, 29, 1561-1566.	2.2	48
68	Relief by botulinum toxin of voiding dysfunction due to prostatitis. <i>Lancet, The</i> , 1998, 352, 625.	6.3	46
69	Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. <i>Movement Disorders</i> , 2012, 27, 1447-1450.	2.2	46
70	The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 42-47.	1.1	46
71	Analysis of blink rate in patients with blepharospasm. <i>Movement Disorders</i> , 2006, 21, 1225-1229.	2.2	45
72	Disappearance of antiphospholipid antibodies syndrome after <i>Helicobacter pylori</i> eradication. <i>American Journal of Medicine</i> , 2001, 111, 163-164.	0.6	43

#	ARTICLE	IF	CITATIONS
73	Mutation screening of the DYT6/ <i>THAP1</i> gene in Italy. <i>Movement Disorders</i> , 2009, 24, 2424-2427.	2.2	43
74	Impulsive and Compulsive Behaviors During Dopamine Replacement Treatment in Parkinson's Disease and Other Disorders. <i>Current Drug Safety</i> , 2012, 7, 63-75.	0.3	43
75	Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. <i>Movement Disorders</i> , 2007, 22, 324-327.	2.2	42
76	Review article The use of botulinum toxin in the alimentary tract. <i>Alimentary Pharmacology and Therapeutics</i> , 1995, 9, 599-604.	1.9	41
77	Phenotypic characterization of DYT13 primary torsion dystonia. <i>Movement Disorders</i> , 2004, 19, 200-206.	2.2	40
78	Olfactory dysfunction in Parkinsonism caused by <i>PINK1</i> mutations. <i>Movement Disorders</i> , 2009, 24, 2350-2357.	2.2	39
79	Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. <i>European Journal of Neurology</i> , 2009, 16, 392-398.	1.7	38
80	Non-DYT1 early-onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature. <i>Movement Disorders</i> , 2006, 21, 1411-1418.	2.2	37
81	Punding and computer addiction in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1217-1218.	2.2	35
82	Phenotypic variability of DYT1-PTD: Does the clinical spectrum include psychogenic dystonia?. <i>Movement Disorders</i> , 2002, 17, 1058-1063.	2.2	34
83	High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1916-1919.	2.2	34
84	Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PARKinson Disease (EXPAND) study. <i>Experimental Gerontology</i> , 2019, 128, 110766.	1.2	32
85	A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PARKinson Disease (EXPAND) ancillary study. <i>GeroScience</i> , 2020, 42, 1323-1334.	2.1	32
86	Subclinical sensory abnormalities in unaffected <i>PINK1</i> heterozygotes. <i>Journal of Neurology</i> , 2008, 255, 1372-1377.	1.8	31
87	Wake and Sleep EEG in Patients With Huntington Disease. <i>Clinical EEG and Neuroscience</i> , 2017, 48, 60-71.	0.9	31
88	Cardiovascular autonomic nervous system evaluation in Parkinson disease and multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 2014, 336, 197-202.	0.3	30
89	Anterior rectocele due to obstructed defecation relieved by botulinum toxin. <i>Surgery</i> , 2001, 129, 524-529.	1.0	29
90	Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. <i>Movement Disorders</i> , 2013, 28, 1142-1145.	2.2	29

#	ARTICLE	IF	CITATIONS
91	Italian family with cranial cervical dystonia: Clinical and genetic study. <i>Movement Disorders</i> , 1999, 14, 820-825.	2.2	28
92	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1232-1235.	2.2	28
93	Unilateral Extradural Motor Cortex Stimulation Is Safe and Improves Parkinson Disease at 1 Year. <i>Neurosurgery</i> , 2012, 71, 815-825.	0.6	28
94	Abnormal gating of somatosensory inputs in essential tremor. <i>Clinical Neurophysiology</i> , 2003, 114, 120-129.	0.7	27
95	Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. <i>Neurological Sciences</i> , 2012, 33, 261-267.	0.9	27
96	Working on asymmetry in Parkinson's disease: randomized, controlled pilot study. <i>Neurological Sciences</i> , 2015, 36, 1337-1343.	0.9	25
97	Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. <i>Movement Disorders</i> , 2004, 19, S146-S156.	2.2	24
98	Freezing of gait in Parkinson's disease: The paradoxical interplay between gait and cognition. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 824-829.	1.1	24
99	Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. <i>Neurological Sciences</i> , 2001, 22, 95-96.	0.9	23
100	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 2108.e1-2108.e5.	1.5	23
101	Long-term effects of pedunculopontine nucleus stimulation for Pisa syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1445-1446.	1.1	23
102	Dopaminergic agents and nutritional status in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1543-1547.	2.2	22
103	Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity. <i>Journal of the Neurological Sciences</i> , 2016, 362, 344-347.	0.3	22
104	Nigro-striatal involvement in primary progressive freezing gait: Insights into a heterogeneous pathogenesis. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 578-584.	1.1	21
105	Idiopathic <sc>Non-task-specific</sc> Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020, 35, 2038-2045.	2.2	21
106	Mild cerebello-thalamo-cortical impairment in patients with normal dopaminergic scans (SWEDD). <i>Parkinsonism and Related Disorders</i> , 2016, 28, 23-28.	1.1	20
107	Genetically determined cholinergic deficiency in the forebrain of C57BL/6 mice. <i>Brain Research</i> , 1994, 637, 181-189.	1.1	19
108	<i>GIGYF2</i> variants are not associated with Parkinson's disease in Italy. <i>Movement Disorders</i> , 2009, 24, 1867-1868.	2.2	19

#	ARTICLE	IF	CITATIONS
109	Lithium Treatment in Patients With Huntington Disease and Suicidal Behavior. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 819-821.	0.7	19
110	Patient's Loss of Empathy Is Associated With Caregiver Burden. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 717-722.	0.5	19
111	Sleep-related modifications of EEG connectivity in the sensory-motor networks in Huntington Disease: An eLORETA study and review of the literature. <i>Clinical Neurophysiology</i> , 2017, 128, 1354-1363.	0.7	19
112	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	0.9	18
113	Emotional Awareness, Relationship Quality, and Satisfaction in Patients With Parkinson's Disease and Their Spousal Caregivers. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 646-649.	0.5	18
114	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 40-43.	1.1	18
115	Punding in Parkinson's disease: The impact of patient's awareness on diagnosis. <i>Movement Disorders</i> , 2010, 25, 1297-1299.	2.2	16
116	Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth. <i>Clinical Neuropharmacology</i> , 2014, 37, 91-95.	0.2	16
117	Subjective Assessment of Sleep in Huntington Disease: Reliability of Sleep Questionnaires Compared to Polysomnography. <i>Neurodegenerative Diseases</i> , 2017, 17, 330-337.	0.8	16
118	Onset and progression of primary torsion dystonia in sporadic and familial cases. <i>European Journal of Neurology</i> , 2006, 13, 1083-1088.	1.7	15
119	Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. <i>Journal of Neurology</i> , 2007, 254, 113-114.	1.8	15
120	Epidemiological, Clinical, and Molecular Study of a Cohort of Italian Parkinson Disease Patients: Association with Glutathione-S-Transferase and DNA Repair Gene Polymorphisms. <i>Cellular and Molecular Neurobiology</i> , 2013, 33, 673-680.	1.7	15
121	Aristotle's illusion reveals interdigit functional somatosensory alterations in focal hand dystonia. <i>Brain</i> , 2013, 136, 782-789.	3.7	15
122	Alpha-synuclein repeat variants and survival in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1053-1057.	2.2	14
123	Pedunculopontine Nucleus Stimulation in Parkinson's Disease Dementia. <i>Biological Psychiatry</i> , 2015, 77, e35-e40.	0.7	13
124	DYT2 screening in early-onset isolated dystonia. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 269-271.	0.7	13
125	Use of ACE-inhibitors and falls in patients with Parkinson's disease. <i>Gait and Posture</i> , 2017, 54, 39-44.	0.6	13
126	Dystonia gravidarum: A new case with a long follow-up. <i>Movement Disorders</i> , 2007, 22, 564-566.	2.2	12



#	ARTICLE	IF	CITATIONS
127	Safety and Efficacy of Rotigotine in Individuals with Parkinson's Disease Aged 75 and Older. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2386-2387.	1.3	12
128	Rapid Eye Movement Sleep Behavior Disorder: A Window on the Emotional World of Parkinson Disease. <i>Sleep</i> , 2015, 38, 287-294.	0.6	12
129	Rehabilitation of hypomimia in Parkinson's disease: a feasibility study of two different approaches. <i>Neurological Sciences</i> , 2016, 37, 431-436.	0.9	12
130	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 735-739.	0.1	11
131	Reliability of Clinical Diagnosis of Dystonia. <i>Neuroepidemiology</i> , 2014, 43, 213-219.	1.1	11
132	Lithium treatment in patients with Huntington's disease and suicidal behavior. <i>Movement Disorders</i> , 2015, 30, 1438-1438.	2.2	11
133	Botulinum toxin in motor disorders. <i>Current Opinion in Neurology</i> , 1999, 12, 447-456.	1.8	11
134	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	11
135	Brain Connectivity Changes in Autosomal Recessive Parkinson Disease: A Model for the Sporadic Form. <i>PLoS ONE</i> , 2016, 11, e0163980.	1.1	10
136	Prevalence of Obsessive-Compulsive Symptoms in Elderly Parkinson Disease Patients: A Case-Control Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 167-175.	0.6	9
137	Management of bladder, prostatic and pelvic floor disorders. <i>Neurotoxicity Research</i> , 2006, 9, 161-172.	1.3	8
138	Rare and serious cardiac side effects during ropinirole titration. <i>Movement Disorders</i> , 2010, 25, 1509-1510.	2.2	8
139	Motor-related sleep disorders in Huntington disease. A comment on: Neute et al.: "Nocturnal agitation in Huntington disease is caused by arousal-related abnormal movements rather than by rapid eye movement sleep behavior disorder" by Neutel et al.. <i>Sleep Medicine</i> , 2016, 20, 172-173.	0.8	8
140	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2020, 127, 881-891.	1.4	8
141	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 70-74.	1.1	8
142	Association of metabolic syndrome with falls in patients with Parkinson's disease. <i>Clinical Nutrition</i> , 2017, 36, 559-563.	2.3	7
143	Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia. <i>Brain Stimulation</i> , 2018, 11, 1192-1194.	0.7	7
144	Prevalence of Huntington's disease in Southern Sardinia, Italy. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 54-57.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel. <i>Parkinsonism and Related Disorders</i> , 2017, 42, 109-111.	1.1	6
146	Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. <i>Brain Sciences</i> , 2021, 11, 416.	1.1	6
147	Botulinum toxin injection for the treatment of chronic anal fissure: uni- and multivariate analysis of the factors that promote healing. <i>International Journal of Colorectal Disease</i> , 2022, 37, 693-700.	1.0	6
148	Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 26.	2.5	5
149	Frameless stereotaxy in subthalamic deep brain stimulation: 3-year clinical outcome. <i>Neurological Sciences</i> , 2021, 42, 259-266.	0.9	5
150	Heart Rate Variability during Wake and Sleep in Huntington's Disease Patients: An Observational, Cross-Sectional, Cohort Study. <i>Neurodegenerative Diseases</i> , 2021, 21, 79-86.	0.8	5
151	Punding Behavior in Bipolar Disorder Type 1: Case Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, E8-E9.	0.9	4
152	Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. <i>Advances in Neurology</i> , 2004, 94, 171-8.	0.8	4
153	Transient alternating hemichorea as presenting sign of progressive supranuclear palsy. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 99-101.	0.1	3
154	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. , 2001, 49, 362.		3
155	Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort. <i>European Journal of Neurology</i> , 2022, 29, 1940-1951.	1.7	3
156	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 421-424.	0.8	2
157	Deep brain stimulation in Fragile X syndrome with tardive dystonia. <i>Neurological Sciences</i> , 2021, 42, 2987-2989.	0.9	2
158	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders. , 2014, , 51-93.		2
159	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering. , 2009, , 112-130.		1
160	FACIAL EMOTION EXPRESSIVENESS AND FACIAL EMOTION RECOGNITION IN PARKINSON'S DISEASE: HOW MUCH DOES ALEXITHYMIA COUNT?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e3-e3.	0.9	1
161	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. <i>Neurological Sciences</i> , 2021, 42, 5177-5181.	0.9	1
162	STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	1

#	ARTICLE	IF	CITATIONS
163	Transcranial Magnetic Stimulation Predicts Functional Recovery after Botulinum Toxin Treatment in Stroke Patients. <i>International Journal of Stroke</i> , 2013, 8, E40-E40.	2.9	0
164	Blepharospasm with non-satisfactory response to treatment: Our experience with IncobotulinumtoxinA. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 665-667.	1.1	0
165	E2â€...Progression of motor subtypes in huntingtonâ€™s disease: a six-year follow-up study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A45.2-A45.	0.9	0